Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope

J M Sabatier; K Mabrouk; M Moulard; H Rochat; J Van Rietschoten; E Fenouillet

doi:10.1006/viro.1996.0496

Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope

Virology. 1996 Sep 15;223(2):406-8. doi: 10.1006/viro.1996.0496.

Authors

J M Sabatier¹, K Mabrouk, M Moulard, H Rochat, J Van Rietschoten, E Fenouillet

Affiliation

¹ CNRS URA 1455, Institut Fédératif de Recherche Jean Roche, Faculté de Médecine Nord, Marseille, France.

PMID: 8806580
DOI: 10.1006/viro.1996.0496

Abstract

Multibranched peptides (SPCs) derived either from the fusion protein (gp41) sequence or from the cleavage sequence of the human immunodeficiency virus type 1 envelope were chemically synthesized and tested for their ability to inhibit both syncytium formation and HIV production in CD4+ cells. The gp41-derived SPCs had no effect. In contrast, an SPC encompassing the envelope cleavage sites strongly inhibited both HIV Env-induced syncytium formation and viral production.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amino Acid Sequence
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / virology
Cells, Cultured
Giant Cells / drug effects
Giant Cells / virology
HIV Envelope Protein gp120 / genetics*
HIV Envelope Protein gp120 / pharmacology*
HIV Envelope Protein gp41 / genetics*
HIV Envelope Protein gp41 / pharmacology*
HIV Infections / virology
HIV-1 / genetics*
Molecular Sequence Data
Recombinant Proteins / chemical synthesis
Recombinant Proteins / pharmacology

Substances

HIV Envelope Protein gp120
HIV Envelope Protein gp41
Recombinant Proteins